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Transitional cell carcinoma (TCC) of the bladder is characterized
by a heterogeneous group of tumours with a varied malignant
potential and natural course. Approximately 80% of the bladder
cancers are low-grade superficial tumours (Heney et al, 1983).
Although these tumours can be resected transurethrally (TURB),
the risk of tumour recurrence is up to 85%, and recurrence often
develops during the first year (Heney et al, 1983; Heney et al
1982). Number (Heney et al, 1982; Koch et al, 1986) and size
(Heney et al, 1982) of tumours and tumour stage (Heney et al
1982; Kiemeney et al, 1993) and grade (Kurth et al, 1995) have a
clear impact on the risk of rapid recurrence. Additionally, early
recurrence after TUR has a prognostic effect itself leading 
to higher risk for recurrences in general (Parmar et al, 1989;
Fitzpatrick et al, 1986). 
The BTA stat® Test (Bion Diagnostic Sciences, Redmond,
Washington, USA) is a one-step, rapid immunochromatographic
assay that detects a bladder tumour associated antigen in human
urine (Sarosdy et al, 1997). The antigen detected by this test has
been identified as human complement factor-H related protein
(hCFHrp). It has been demonstrated that hCFHrp is produced and
secreted by several human bladder cancer cell lines, but not by
normal human epithelial keratinocytes (Kinders et al, 1997a,
1997b). It has also been demonstrated by in situ hybridization that
bladder tumours produce hCFHrp (Kinders et al, 1998). The
function of this protein is similar to that of human complement
factor H, i.e. by down-regulating the alternative complement
pathway this protein may help bladder cancer cells escape lysis by
the host immune system. Thus, it seems possible that expression of
hCFHrp, detected by the BTA stat Test, could also be used as a
prognostic marker. 
The BTA stat Test has been shown to have equal or superior
sensitivity to that of voided urine cytology in detecting primary
and recurrent bladder tumours (Sarosdy et al, 1997; Pode et al,
1999; Raitanen et al, 2000), whereas the specificity has been
decreased by benign genitourinary condition (Sarosdy et al, 1997)
and intravesical BCG treatment (Pode et al, 1999). Although it has
also been suggested that false positive BTA stat Test in patients
under follow-up for TCC might predict tumour recurrence
(Sarosdy et al, 1997), the idea of BTA stat Test as a prognostic
marker on primary bladder tumours has not been introduced or
reported earlier. The aim of this study was to evaluate the role of
tumour grade, stage, size, and number, and more interestingly, to
test our hypothesis that BTA stat Test result might be of prognostic
importance. 
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MATERIALS AND METHODS 
This was a prospective, multi-centre study conducted by
FinnBladder Group at 18 medical institutions between 1997 and
1999. One hundred and sixteen patients with confirmed primary
transitional cell carcinoma of urinary bladder were consecutively
recruited in accordance with the Declaration of Helsinki. Tumour
had to be confined to the bladder mucosa (Ta) or lamina propria
(T1) and curatively treatable by TURB. A total number of 19
patients were excluded from analysis since they were lost to
follow-up or were treated with series of intravesical instillations
leaving 97 eligible patients, of which 73 (75.3%) were men (mean
age 66 years, range 38–88) and 24 (25.0%) were women (mean
age 68 years, range 21–86). This study was approved by each local
Human Investigations Committee and all the patients gave written
informed consent. Five patients (5.2%) have received a single
instillation of chemotherapeutic agent immediately after TURP,
however, as there were only very few patients with this treatment,
those patients were not analysed separately here. Standard follow-
up policy was obtained. According to the grade and stage of
primary tumour, cystoscopy was performed every 3–6 months for
2 years and if no recurrences were observed during this time the
interval was prolonged to 6–12 months. 
Freshly voided urine samples were obtained a minimum of 2
weeks after diagnostic cystoscopy, prior to transurethral resection
of tumour (TURB) and split for culture (to exclude urine infec-
tion), cytological analysis and BTA stat testing. The BTA stat Test
was performed at each institution by a trained nurse according to
the manufacturer’s instructions by adding five drops of an
untreated voided urine sample into the sample well of the dispos-
able test device using the disposable pipette provided. Five
minutes after the addition of urine to the sample well, a qualita-
tive (positive or negative) interpretation was performed. The
cytopathological results were analysed by central review (RA)
blinded to the results of the cystoscopy, local cytology and the
BTA stat Test result. Positive voided urinary cytology was defined
as Papanicolaou classification 4 and 5. Tumour characteristics
such as size and number were recorded. Tumours were graded
according to the World Health Organization grading system and
staged according to TNM classification at each of the participating
hospitals (Mostofi et al, 1973; UICC, 1978). 
Primary end-point was time to first recurrence, i.e. the disease-
free interval (DFI). The Kaplan–Meier method was used to obtain
the estimated DFI curves for the studied variables such as BTA stat
Test result and the well known prognostic factors (histological
grade, stage, tumour size and number). A further stratification was
applied to examine the relationship between tumour grade and
BTA stat Test and their effects on DFI. A number of statistical
significance tests have been proposed which compare two
Kaplan–Meier curves (Parmar and Machin, 1995). The most
widely used testing method, the log-rank test, emphasizes recur-
rences in the tail of the curves. In our study, we wanted to give
more weight to the earlier part of the curve where there are larger
number of patients at risk. We also anticipate that BTA stat Test
may help to detect the particular risk of very short DFI. Therefore,
we used Breslow version of the generalized Wilcoxon statistic test,
which places more emphasis on the information at the beginning
of the DFI curve. 
The Cox proportional hazard model (Parmar and Machin, 1995)
was used in the multivariate analysis for testing the independence
and significance of the effects of the aforementioned variables on
recurrence. The model is reported using hazard ratios and their
95% confidence intervals (CI). Hazard ratios demonstrate the rela-
tive risk for recurrence. P-value of the likelihood ratio test is also
reported to confirm the variable as an appropriate prognostic
factor. Statistical analysis was performed with SPSS for Windows
software (SPSS, 1999). 
RESULTS 
The BTA stat Test was positive in 73 cases (75.3%) of the 97
patients at the diagnosis of primary bladder carcinoma, whereas
only 20 patients (20/86, 23.3%) presented with concurrent positive
cytology. The mean follow-up time was 13 months (range 1–48
months, median 9.0). Sixty-six (68.0%) patients had recurrence
with the mean time of 8 months (range 1–28 months, median 7).
The mean follow-up time in those with no recurrence was 27
months (range 6–48 months, median 28). Distribution of patients
according to tumour characteristics, BTA stat Test and cytology is
summarized in Table 1. 
The Kaplan–Meier plot showed that disease-free interval was
significantly longer if the patient had negative BTA stat Test, as
according to the Kaplan–Meier estimates the patients with positive
BTA stat Test had 63.0% risk of recurrence during the first year 
of follow-up compared to 39.1% risk of the ones with negative
testing (P = 0.002, Figure 1A). The difference in DFI between the
patients with low-grade and high-grade tumours was also signifi-
cant, since the patients with grade 1,2 and 3 tumours had 44.2%,
64.6% and 88.9% risks of recurrence during the first year, respec-
tively (P = 0.0005, Figure 1B). DFI was not affected by stage of
tumour as shown by the quite similar risks of recurrence of 56.0%
and 61.0% in patients with Ta and T1 tumours (P = 0.60).
Although the disease free probability was 53.1% in the patients
with single tumour compared to that of 35.2% of patients with
multiple tumours, the difference was not statistically significant 
(P = 0.284). Accordingly, no statistically significant distinction
could be made either on the basis of tumour size in spite of the
consistent trend observed in the disease free estimates, which were
at one year 58.8%, 43.2% and 29.7% for tumours smaller than 1
cm, for tumours 1–3 cm, and for tumours larger than 3 cm, respec-
tively (P = 0.131). In addition, the impact of tumour size on DFI
became more clear if the cut-off point was set on 1 cm, as 41.2%
and 61.5% of the patients with tumour size ≤ 1 cm or > 1 cm had
Table 1 Distribution of patients according to grade, stage, number and size
of tumour, and BTA stat Test and cytology. 
Number (%) Number (%) 
Grade: Size: 
1 46 (47.4) < 1 cm 25 (25.8) 
2 42 (43.3) < 3 cm 44 (45.4) 
3 9 (9.3) > 3 cm 26 (26.8) 
unknown 2 (2.1)
Stage: 
Ta 56 (57.7) BTA stat
T1 36 (37.1) Positive 73 (75.3) 
unknown 5 (5.3) Negative 24 (24.7) 
Number: Cytology 
1 62 (63.9) 1–3 66 (68.1) 
2–3 21 (21.6) 4–5 20 (20.6) 
> 4 12 (12.4) unknown 11 (11.3) 
unknown 2 (2.1) recurrence during the first year, respectively (P = 0.064). 
Although the number of BTA stat Test negative patients was low
among grade 2 tumours (7/42), the BTA stat Test result appeared
to divide the patients with grade 2 tumours into two statistically
significant prognostic groups (P = 0.041, Figure 2B). The risk of
recurrence was 68.6% in the patients with positive BTA stat Test
as compared to 42.9% in the patients with negative results, the
latter percentage being quite similar to risk of patients with low
grade tumours (44.2%). However, no such statistical distinction
according to the BTA stat Test result could be made among the low
grade tumours (P = 0.176, Figure 2A). By contrast, if grade 1 and
2 tumours were analysed as a single group, the difference between
BTA stat Test positive and negative patients remained significant
(P = 0.006). All nine patients with grade 3 tumours had positive
BTA stat Test result, and all but one of them had recurrence. The
effect of BTA stat Test on DFI was not therefore analysed sepa-
rately among these patients. 
DFI analysis of co-variates was performed according to the Cox
model for all the patients for whom complete data on all the vari-
ables were available. There was a substantial proportion of patients
missing review cytology. In addition, as positive cytology was
completely correlated to positive BTA stat Test in our earlier study
(Raitanen et al, 2000) and BTA stat Test was regarded here as an
alternative to cytology, cytology was not included in multivariate
analysis. Histological grade and BTA stat Test result were both
independently related to the DFI. Tumour grade implied 1.7-and
3.9-fold risk of recurrence for grade 2 and 3 tumours compared to
tumours of low grade. A positive BTA stat Test result implied a
2.2-fold risk for recurrence compared to a negative test. In concor-
dance with Kaplan–Meier analyses, the DFI was not affected in
the Cox model by size or number of tumours, nor was the tumour
stage of prognostic significance (Table 2). 
DISCUSSION 
We report here the results of a prospective multicentre study in
which the factors effecting DFI were analysed. Ninety-seven
eligible patients with primary superficial bladder cancer with
mean follow-up time of 13 months were evaluated. We found that,
in addition to the well-known prognostic factor predicting early
recurrence, tumour grade, also the positive BTA stat Test predicted
shorter DFI. The independence of the two factors in predicting
short-term recurrence was noteworthy, since in our earlier analysis
(Raitanen et al, 2000) the sensitivity of BTA stat Test was essen-
tially related to the grade of tumour. However, in this study exam-
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Figure 1 Kaplan–Meier plot of the disease-free interval of 92 patients
according to BTA stat Test (A) and tumour grade (B). The difference in curves
is significant (A: P = 0.002, B: P = 0.0005). The number of patients at risk at
the beginning of each 3-month period is indicated above the time axis 
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Figure 2 Kaplan–Meier plot of the disease-free interval of patients
according to BTA stat Test and tumour grade. (A) Patients with grade 1
tumours (P = 0.176). (B) Patients with grade 2 tumours. The difference in
curves in (B) is significant (P = 0.041). The number of patients at risk at the
beginning of each 3-month period is indicated above the time axis. Positive
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ining DFI, the presence of the antigen detected by the BTA stat
Test showed a potential in distinguishing low and high risk groups
among patients with grade 2 tumours. 
Superficial bladder cancer includes a heterogeneous group of
tumours that vary considerably in histological appearance and
malignant potential. The tumour stage (Heney et al, 1982;
Kiemeney et al, 1993; Lutzeyer et al, 1982; Malmström et al,
1987) and grade (Kiemeney et al, 1993; Kurth et al, 1995;
Lutzeyer et al, 1982) as well as the size (Heney et al, 1982) and
number (Heney et al, 1982; Koch et al, 1986; Kiemeney et al,
1993; Lutzeyer et al, 1982) of tumours are well known prognostic
factors, in that, multiple, large (> 3 cm), high grade tumours that
invade lamina propria (T1) have a shorter disease free interval and
more recurrences in general, and more importantly, a higher
progression rate and even mortality. Our results confirm the effect
of histological grade on the natural course of the disease, as
tumour grade was strong predictor for short DFI. However, the
impact of number or size of tumours, was not of statistical signifi-
cance, although differences in DFI were notable. This may be 
due, at least partly, to the rather small number of patients in the
analysis. Moreover, due to the short follow-up time here,
evaluating anything but DFI is not justified. 
The risk of recurrence is high after TURB (Heney et al, 1982)
and although the risk for further recurrences and for progression
decreases as the number of years without recurrences increases
(Morris et al, 1995), tumour may recur and even progress after five
years free of the disease (Thompson et al, 1993). The overall risk
of 68.0% for recurrence during the first year is in accordance with
previous reports (Heney et al, 1982) and suggests that our prospec-
tive study with consecutive patients from 18 centres represents
well the population of patients being monitored for conservatively
treated superficial bladder cancer. In addition, the mean follow-up
time was over 2 years in patients with no recurrence. 
In accordance with other studies (Sarosdy et al, 1997; Pode 
et al, 1999; Raitanen et al, 2000), the sensitivity of BTA stat Test
was superior to that of cytology, in that BTA stat Test and cytology
detected 75.3% and 23.3% of tumours, respectively. To date, little
has been reported about the prognostic effect of BTA stat Test.
It has been suggested that it may be possible that the BTA stat
Test predicts tumour recurrence (Pode et al, 1999). It has also 
been reported that positive BTA stat Test in a patient with nega-
tive cystoscopy may predict oncoming recurrence. Sarosdy et al
reported that in their study of 107 patients under follow-up for
bladder cancer but with no sign of recurrence at cystoscopy, 32
(29.9%) had false positive BTA stat Test, of which 31 % developed
recurrence between 3 and 12 months later (Sarosdy et al, 1997). It
is noteworthy that in their study, the current status of the disease on
these patients was evaluated only on the basis of cystoscopy. 
The antigen detected by the BTA stat Test has been identified as
human complement factor-H related protein (hCFHrp), a varient
of human complement factor H (FH) by partial amino acid
sequence analysis. The composition, structure, and function of
hCFHrp are similar to those of human complement FH and studies
have shown that expression of proteins with CFH-like activities
may confer selective growth advantage to cancer cells in vivo by
decreasing complement activity, thus allowing the cancer cells to
escape lysis by the host immune system (Kinders et al, 1997a;
1997b; 1998). 
FH, a soluble negative regulator of the complement system, is
produced and secreted by most TCCs of the bladder (Kinders et al,
1998). In situ hybridization experiments have shown that bladder
tumours also produce FH messager RNA (mRNA), while normal
bladder epithelium produces little or no mRNA (Corey et al,
1998). Although the significance of this phenomenon with regard
to both biochemistry and cancer biology remains to be established,
the data available suggest that factor H plays an important role in
tumour survival (Kinders et al, 1997a, 1997b, 1998). So it can be
suggested that when escaping lysis by the immune system the
seeded cells during TURB or small residual tumours will survive
more often and thus develop recurrency faster than those not
secreting factor H. It can also be speculated that positive BTA stat
Test might be associated with tumourgenesis of bladder epithelium
and therefore possibly predict development of a new tumour in
another place. These speculations will, however, be the topic of
further research. 
Unfortunately our short follow-up time does not allow discus-
sion of the long-term prognostic effect of these studied factors.
However, these findings confirm the earlier reports of histological
grade as a prognostic marker affecting DFI. More importantly, our
results suggest that expression of human complement factor H
related protein detected by BTA stat Test could be used for deter-
mining follow-up policy in some cases. Compared to other prog-
nostic factors, the presence of the BTA antigen may have two
utilities: detection of new tumours and prediction of a shorter DFI
for tumours expressing hCFHrp. 
As interesting as the prognostic dimension of the BTA stat Test
is, there are some aspects that must be kept in mind as the clinical
usability of this test is discussed. A majority (75.3% here) of the
patients with primary bladder cancer are BTA stat positive,
predicting shorter DFI, and the remaining 24.7% with a negative
test predict better outcome. However, a test detecting the smaller
group of patients with poor outcome would be more useful in clin-
ical practice. Additionally, as a negative BTA stat Test predicts
better outcome, it seems possible to decrease the number of cysto-
scopies by prolonging the interval in these patients. The safest
group of patients would be those with grade 1 tumour, however,
we failed to prove any significant difference in DFI by BTA stat
Test result in this group. Furthermore, as all high grade tumours
tested positive, the prognostic use of BTA stat Test is not justified
Table 2 Multivariate (Cox model) disease free interval (DFI) analysis of 92
patients with conservatively treated superficial bladder cancer. Hazard ratios
(95% CI) and P value for additional information in multivariate analysis are
given for each covariate 
Variable Hazard ratio 95% Confidence interval P-value 
BTA stat Test 0.02 
– negative 1 
– positive 2.2 1.1–4.6 
Grade 0.02 
– 11  
– 2 1.7 1.0–3.1 
– 3 3.9 1.5–10.0 
Stage 0.09 
– Ta 1 
– T1 0.6 0.3–1.1 
Number 0.98 
– Single 1 
– multiple 1.0 0.6–1.7 
Size 
– ≤ 1 cm 1 0.46 
– ≤ 3 cm 1.0 0.5–2.0 
– > 3 cm 1.5 0.7–3.2 556 M-P Raitanen et al 
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in these tumours. By contrast and more interestingly, the decreased
risk (42.9% vs 68.6%) for short-term recurrence among patients
with grade 2 tumours testing negative could have clinical implica-
tions, although the majority (83.3%) of the patients with grade 2
tumours tested positive. In addition, a similar statistically signifi-
cant distinction could be made on the basis of the negative test
result if grade 1 and 2 tumours were grouped and analysed
together. There appears to be a relationship between grade and
BTA  stat Test result according to our results; while
negative BTA stat Test implies decreased risk of recurrence irre-
spective of grade, the positive test indicates increased risk of recur-
rence, the magnitude of which is determined by grade. 
We found that the BTA stat Test is not only sensitive for the
diagnosis of primary bladder cancer but also has prognostic utility
in patients with negative results. Although the clinical importance
of the observed independent prognostic dimension of the BTA stat
Test remains somewhat obscure, our data further underlines the
role of BTA stat Test as a more potent diagnostic tool (in most
cases) than cytology in the diagnosis of bladder cancer. The BTA
stat Test also helped to differentiate high grade and low risk
subgroups for short DFI in patients with grade 2 tumours.
Therefore, it might be suggested that BTA stat Test could replace
routine cytology in the diagnosis of bladder cancer, and possibly,
could also be used as a tool together with other prognostic markers
in determining patients follow-up policy. The possible contribution
of BTA stat Test should be viewed in the current treatment context,
where predictability of the course of the disease remains unsatis-
factory. In addition, there is an urgent need for reduction of the
large number of negative follow-up cystoscopies, which are costly
and produce patient discomfort. One possibility could be in
increasing the interval between follow-up cystoscopies in those
having negative test result. However, prospective trials are needed
to confirm the utility of BTA stat Test in these connections. 
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